Finally, ICB (both anti-CTLA4 and anti-PD1 antibodies) and MDSC-targeted therapy could then be utilized to break immunological tolerance and permit CD8+ cytolytic activity on PCa cells. Here, CTLA4 is linked to posterior cortical atrophy.